Anti-tumor effects of HDAC6-specific inhibitors on prostate cancer cells have been observed (Chuang et al., 2013; Seidel et al., 2016; Wu et al., 2018); however, the role of TGF-β and its connection to HDAC6 in prostate cancer progression have not been addressed before. Here, TGFB1 is linked to prostate carcinoma.